BCL-2抑制剂在血液恶性肿瘤中的靶向治疗应用及作用机制

doi:10.11904/j.issn.1002-3070.2022.05.011

实用肿瘤学杂志 ›› 2022, Vol. 36 ›› Issue (5): 452-457.doi: 10.11904/j.issn.1002-3070.2022.05.011

BCL-2抑制剂在血液恶性肿瘤中的靶向治疗应用及作用机制

何晓晴¹, 柯鹏² 综述, 张新友¹ 审校

1.暨南大学第二临床医学院(深圳市人民医院血液内科)(深圳 518000);
2.苏州大学附属第一医院血液科

收稿日期:2022-01-25 修回日期:2022-09-02 出版日期:2022-10-28 发布日期:2022-11-10
通讯作者: 张新友,E-mail:zxy0518@live.cn
作者简介:何晓晴,女,(1996-),硕士研究生,从事血液肿瘤治疗的研究。
基金资助:
深圳市科技计划项目(编号:JCYY202103241202100290)

The targeted therapy and mechanism of BCL-2 inhibitor in hematological malignancies

HE Xiaoqing¹, KE Peng², ZHANG Xinyou¹

1. The Second Clinical Medical College,Jinan University(Department of Hematology,Shenzhen People's Hospital),Shenzhen 518000,China;
2. Department of Hematology,The First Affiliated Hospital of Soochow University

Received:2022-01-25 Revised:2022-09-02 Online:2022-10-28 Published:2022-11-10

摘要/Abstract

摘要： 细胞凋亡受到抑制是血液恶性肿瘤细胞的突出特征。B细胞淋巴瘤-2(B-cell lymphoma-2,BCL-2)是细胞凋亡关键性蛋白调节因子,在多种血液恶性肿瘤中有不同程度的表达。高表达BCL-2的肿瘤细胞抗细胞凋亡能力显著增强,靶向抑制BCL-2成为抗血液肿瘤的研究热点之一。维奈克拉是首个获批上市的BCL-2抑制剂(BCL-2 inhibitor,BCL-2i),用于慢性淋巴细胞白血病、急性髓系白血病及骨髓增生异常综合征的治疗。研究表明维奈克拉对其他血液恶性肿瘤如B细胞非霍奇金淋巴瘤及多发性骨髓瘤也具有抗肿瘤活性。本文就BCL-2抗凋亡机制、BCL-2i在血液恶性肿瘤中的临床应用以及BCL-2i耐药的可能机制作一简要综述。

关键词: B细胞淋巴瘤-2, 细胞凋亡, 维奈克拉, 血液恶性肿瘤

Abstract: Inhibition of apoptosis is a prominent feature of hematological malignancies.B-cell lymphoma-2(BCL-2)is a key protein regulator of apoptosis and is expressed to varying degrees in a variety of hematological malignancies.The anti-apoptotic ability of tumor cells with high expression of BCL-2 is significantly enhanced,and targeted inhibition of BCL-2 has become one of the research hotspots in anti-hematological tumors.Venetoclax(VEN)is the first BCL-2 inhibitor(BCL-2i)approved for the treatment of chronic lymphocytic leukemia,acute myeloid leukemia and myelodysplastic syndromes.Studies have shown that VEN also has antitumor activity against other hematological malignancies such as B-cell non-Hodgkin lymphomas and multiple myeloma.This article briefly reviews the anti-apoptosis mechanism of BCL-2,the clinical application of BCL-2i in hematological malignancies,and the possible mechanism of BCL-2i resistance.

Key words: B-cell lymphoma-2, Apoptosis, Venetoclax, Hematological malignancies

中图分类号:

R733

何晓晴, 柯鹏, 张新友. BCL-2抑制剂在血液恶性肿瘤中的靶向治疗应用及作用机制[J]. 实用肿瘤学杂志, 2022, 36(5): 452-457.

HE Xiaoqing, KE Peng, ZHANG Xinyou. The targeted therapy and mechanism of BCL-2 inhibitor in hematological malignancies[J]. Journal of Practical Oncology, 2022, 36(5): 452-457.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.05.011

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I5/452

参考文献

1 Roberts AW.Therapeutic development and current uses of BCL-2 inhibition[J].Hematology,2020,2020(1):1-9.
2 Kale J,Osterlund EJ,Andrews DW.BCL-2 family proteins:changing partners in the dance towards death[J].Cell Death Differ,2018,25(1):65-80.
3 Valentin R,Grabow S,Davids MS.The rise of apoptosis:targeting apoptosis in hematologic malignancies[J].Blood,2018,132(12):1248-1264.
4 Ferrarini I,Rigo A,Visco C.The mitochondrial anti-apoptotic dependencies of hematologic malignancies:from disease biology to advances in precision medicine[J].Haematologica,2022,107(4):790-802.
5 Diepstraten ST,Anderson MA,Czabotar PE,et al.The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs[J].Nat Rev Cancer,2022,22(1):45-64.
6 Roberts AW,Wei AH,Huang DCS.BCL2 and MCL1 inhibitors for hematologic malignancies[J].Blood,2021,138(13):1120-1136.
7 Moia R,Patriarca A,Schipani M,et al.The biology of chronic lymphocytic leukemia:diagnostic and prognostic implications[J].Cancer J,2021,27(4):266-274.
8 Klein U,Lia M,Crespo M,et al.The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia[J].Cancer Cell,2010,17(1):28-40.
9 Stilgenbauer S,Eichhorst B,Schetelig J,et al.Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion:a multicentre,open-label,phase 2 study[J].Lancet Oncol,2016,17(6):768-778.
10 Roberts AW,Davids MS,Pagel JM,et al.Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia[J].N Engl J Med,2016,374(4):311-322.
11 Roberts AW,Ma S,Kipps TJ,et al.Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables[J].Blood,2019,134(2):111-122.
12 Seymour JF,Ma S,Brander DM,et al.Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia:a phase 1b study[J].Lancet Oncol,2017,18(2):230-240.
13 Seymour JF,Kipps TJ,Eichhorst B,et al.Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia[J].N Engl J Med,2018,378(12):1107-1120.
14 Al-Sawaf O,Zhang C,Tandon M,et al.Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia(CLL14):follow-up results from a multicentre,open-label,randomised,phase 3 trial[J].Lancet Oncol,2020,21(9):1188-1200.
15 Jain N,Keating M,Thompson P,et al.Ibrutinib and venetoclax for first-line treatment of CLL[J].N Engl J Med,2019,380(22):2095-2103.
16 Hillmen P,Rawstron AC,Brock K,et al.Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia:the CLARITY study[J].J Clin Oncol,2019,37(30):2722-2729.
17 Deng J,Isik E,Fernandes SM,et al.Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia[J].Leukemia,2017,31(10):2075-2084.
18 Ma S,Seymour JF,Brander DM,et al.Efficacy of venetoclax plus rituximab for relapsed CLL:5-year follow-up of continuous or limited-duration therapy[J].Blood,2021,138(10):836-846.
19 Izzo F,Landau DA.A BAX door to venetoclax resistance[J].Blood,2022,139(8):1124-1126.
20 Mato AR,Sharman JP,Biondo JML,et al.The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia:post-hoc analyses from the phase III MURANO study[J].Haematologica,2022,107(1):134-142.
21 Konopleva M,Pollyea DA,Potluri J,et al.Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia[J].Cancer Discov,2016,6(10):1106-1117.
22 Lee JB,Khan DH,Hurren R,et al.Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production[J].Blood,2021,138(3):234-245.
23 Dinardo CD,Jonas BA,Pullarkat V,et al.Azacitidine and venetoclax in previously untreated acute myeloid leukemia[J].N Engl J Med,2020,383(7):617-629.
24 Wei AH,Montesinos P,Ivanov V,et al.Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy:a phase 3 randomized placebo-controlled trial[J].Blood,2020,135(24):2137-2145.
25 Chua CC,Roberts AW,Reynolds J,et al.Chemotherapy and venetoclax in elderly acute myeloid leukemia trial(CAVEAT):a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy[J].J Clin Oncol,2020,38(30):3506-3517.
26 Cherry EM,Abbott D,Amaya M,et al.Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia[J].Blood Adv,2021,5(24):5565-5573.
27 Dinardo CD,Pratz K,Pullarkat V,et al.Venetoclax combined with decitabine or azacitidine in treatment-naive,elderly patients with acute myeloid leukemia[J].Blood,2019,133(1):7-17.
28 Thijssen R,Diepstraten ST,Moujalled D,et al.Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias[J].Blood,2021,137(20):2721-2735.
29 Pei S,Pollyea DA,Gustafson A,et al.Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia[J].Cancer Discov,2020,10(4):536-551.
30 Davids MS,Roberts AW,Seymour JF,et al.Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma[J].J Clin Oncol,2017,35(8):826-833.
31 Tam CS,Anderson MA,Pott C,et al.Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma[J].N Engl J Med,2018,378(13):1211-1223.
32 Davids MS,Roberts AW,Kenkre VP,et al.Long-term follow-up of patients with relapsed or refractory non-hodgkin lymphoma treated with venetoclax in a phase I,first-in-human study[J].Clin Cancer Res,2021,27(17):4690-4695.
33 Fowler N.BCL-2 inhibition in follicular lymphoma:Can we tip the scales?[J].Blood,2020,136(23):2598-2600.
34 Blombery P,Birkinshaw RW,Nguyen T,et al.Characterization of a novel venetoclax resistance mutation(BCL2 Phe104Ile)observed in follicular lymphoma[J].Br J Haematol,2019,186(6):e188-e191.
35 Morschhauser F,Feugier P,Flinn IW,et al.A phase II study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma[J].Blood,2021,137(5):600-609.
36 Touzeau C,Moreau P.Sensitivity to venetoclax:The B-side of myeloma?[J].Blood,2021,137(26):3582-3583.
37 Gupta VA,Barwick BG,Matulis SM,et al.Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression[J].Blood,2021,137(26):3604-3615.
38 Matulis SM,Gupta VA,Nooka AK,et al.Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax[J].Leukemia,2016,30(5):1086-1093.
39 Slomp A,Moesbergen LM,Gong JN,et al.Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting[J].Blood Adv,2019,3(24):4202-4214.

[1]	陈雪健, 王伟, 周健, 李宁, 张浩鹏, 徐力善. 瑞戈非尼联合哌立福辛诱导人肝癌HepG2细胞凋亡的分子机制研究[J]. 实用肿瘤学杂志, 2021, 35(5): 408-413.
[2]	金升烨, 庞达. 溶瘤病毒诱导肿瘤凋亡及激活抗肿瘤免疫机制的研究进展[J]. 实用肿瘤学杂志, 2021, 35(5): 462-467.
[3]	胡启辉, 杜毅超, 贺凯, 付文广, 夏先明. 内质网应激在肝癌中的作用[J]. 实用肿瘤学杂志, 2021, 35(2): 160-164.
[4]	庞晨, 张秀玲, 张锡流. 铁皮石斛抑制上皮源性恶性肿瘤的研究进展[J]. 实用肿瘤学杂志, 2020, 34(4): 362-367.
[5]	王飞, 朱贲贲. 丙泊酚经HIF-1α信号通路对头颈鳞状细胞癌SCC-74细胞增殖、凋亡与侵袭的影响[J]. 实用肿瘤学杂志, 2020, 34(2): 120-125.
[6]	黄梨, 龙佑梅, 付义霞, 夏良斌. 紫檀芪对卵巢癌SKOV3细胞凋亡和糖酵解的影响及机制研究[J]. 实用肿瘤学杂志, 2019, 33(6): 502-507.
[7]	安巍巍, 唐雅莉, 赵莲花, 杨悦, 王新玲. 红松松塔提取物多聚苯丙素-多糖复合物诱导人乳腺癌MCF-7细胞凋亡[J]. 实用肿瘤学杂志, 2019, 33(4): 289-293.
[8]	梁语丝, 谭永刚, 邹华伟审校. 低剂量化疗作用机制的研究进展[J]. 实用肿瘤学杂志, 2017, 31(6): 538-542.
[9]	王吉锡, 邓伟生, 王凤儒, 史之茂, 孟丹, 徐强, 张玉瑶. 甘草提取物的有效部位诱导人宫颈癌HeLa细胞株凋亡及对凋亡相关蛋白Caspase-3和Caspase-9表达的影响[J]. 实用肿瘤学杂志, 2017, 31(5): 390-395.
[10]	张绪良, 胡亚华, 黄丹青. 苏林酸在NF-κB对人乳腺癌TNF-α诱导细胞凋亡增敏中的相关作用[J]. 实用肿瘤学杂志, 2017, 31(2): 102-106.
[11]	刘冰梅, 程雪, 邢荣贵综述, 杨晶审校. 角化棘皮瘤消退机制的研究进展[J]. 实用肿瘤学杂志, 2017, 31(1): 83-87.
[12]	赵相轩, 温锋, 毛晓楠综述, 卢再鸣审校. 细胞凋亡在原发性肝癌治疗中的作用研究进展[J]. 实用肿瘤学杂志, 2016, 30(5): 448-452.
[13]	赵相轩,温锋综述,卢再鸣审校. 细胞凋亡在胰腺癌治疗中的作用[J]. 实用肿瘤学杂志, 2016, 30(4): 375-379.
[14]	郑育强, 丁锦辉, 宋磊. 增强细胞缝隙连接功能对三阴性乳腺癌细胞放疗敏感性的研究[J]. 实用肿瘤学杂志, 2016, 30(2): 128-134.
[15]	赵云, 温锋, 赵相轩, 郭启勇. TRAIL及其相关凋亡调节机制在胆管癌中的研究进展[J]. 实用肿瘤学杂志, 2015, 29(1): 49-52.

BCL-2抑制剂在血液恶性肿瘤中的靶向治疗应用及作用机制

The targeted therapy and mechanism of BCL-2 inhibitor in hematological malignancies

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价